Skip to main content
SpringerLink
Log in

MK 869

Aprepitant, L 754030, MK 0869

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Elwood W. Dawn of a new era with substance P antagonists in depression?. Inpharma. 1154: 9–10, 12 Sep 1998

    Google Scholar 

  2. Feighner JP. Substance P. European Neuropsychopharmacol 8 (Suppl 2): 85, Nov 1998

    Article  Google Scholar 

  3. Tattersall FD, Rycroft W, Hale JJ, et al. The NK1 receptor antagonist L-754,030 and its N-phosphoryl prodrug L-758,298 inhibit acute and delayed cisplatin-induced emesis in the ferret. 34th AnnualMeeting of the American Society of Clinical Oncology 17: 253, 16 May 1998

    Google Scholar 

  4. Navari RM, Reinhardt RR, Gralla RJ, Kris MG. L-754,030 Antiemetic Trials Group. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. New Engl J Med 340: 190–195, 21 Jan 1999

    Article  PubMed  CAS  Google Scholar 

  5. Campos D, Rodrigues-Pereira J, Carides AD, Gertz BJ. Prevention of chemotherapy-induced emesis by the oral NK-1 antagonist MK-869. 36th Annual Meeting of the American Society of Clinical Oncology. 19: 600, 20 May 2000

    Google Scholar 

  6. Chawla SP, Gralla RJ, Hesketh PJ, et al. Establishing the dose of the oral NK-1 antagonist MK-869 for chemotherapy induced nausea and vomiting. 37th Annual Meeting of the American Society of Clinical Oncology. 20: 383 (plus oral presentation), Part 1, 12 May 2001

    Google Scholar 

  7. Martin AR, Cai B, Pearson JD, et al. Effect of an NK-1 antagonist (MK-0869) on patient-reported impact of chemotherapy- induced nausea and vomiting on daily life. 37th Annual Meeting of the American Society of Clinical Oncology. 20: 406, Part 1, 12 May 2001

    Google Scholar 

  8. Cutler NR, Kramer MS, Reines SA, Sramek JJ. Single site results from a multicenter study of efficacy and safety of MK- 869, and NK-1 antagonist, in patients with major depressive disorder. Int J Neuropsychopharmacol 3 (Suppl 1): 7, Jul 2000

    Google Scholar 

  9. Rupniak NMJ, Kramer MS. Discovery of the anti-depressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trend Pharmacol Sci 20: 485–490, No. 12, Dec 199

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

MK 869. Drugs R&D 3, 200–203 (2002). https://doi.org/10.2165/00126839-200203030-00013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200203030-00013

Keywords

Search

Navigation